Literature DB >> 17909040

The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor.

Seema Paliwal1, Ramesh C Kovi, Bharath Nath, Ya-Wen Chen, Brian C Lewis, Steven R Grossman.   

Abstract

The alternative reading frame (ARF) tumor suppressor exerts both p53-dependent and p53-independent activities critical to the prevention of cancer in mice and humans. Recent evidence from mouse models suggests that when p53 is absent, further loss of ARF can widen the tumor spectrum, and potentiate invasion and metastasis. A major target of the p53-independent activity of ARF is the COOH-terminal binding protein (CtBP) family of metabolically regulated transcriptional corepressors, which are degraded upon acute exposure to the ARF protein. CtBPs are activated under conditions of metabolic stress, such as hypoxia, to repress epithelial and proapoptotic genes, and can mediate hypoxia-induced migration of cancer cells. The possibility that ARF could suppress tumor cell migration as part of its p53-independent activities was thus explored. Small-interfering RNA (siRNA)-mediated knockdown of ARF in human lung carcinoma cells led to increased cell migration, especially during hypoxia, and this effect was blocked by concomitant treatment with CtBP2 siRNA. Introduction of ARF into p53 and ARF-null human colon cancer cells inhibited hypoxia-induced migration. Furthermore, overexpression of CtBP2 in ARF-expressing cells enhanced cell migration, and an ARF mutant defective in CtBP-family binding was impaired in its ability to inhibit cell migration induced by CtBP2. ARF depletion or CtBP2 overexpression was associated with decreased PTEN expression and activation of the phosphatidylinositol 3-kinase pathway, and a phosphatidylinositol 3-kinase inhibitor blocked CtBP2-mediated cell migration. Thus, ARF can suppress cell migration by antagonizing CtBP2 and the phosphatidylinositol 3-kinase pathway, and these data may explain the increased aggressiveness of ARF-null tumors in mouse models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909040     DOI: 10.1158/0008-5472.CAN-07-1743

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

2.  CtBP1 interacts with Ikaros and modulates pituitary tumor cell survival and response to hypoxia.

Authors:  Katie Dorman; Zhongyi Shen; Caimei Yang; Shereen Ezzat; Sylvia L Asa
Journal:  Mol Endocrinol       Date:  2012-02-02

3.  Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression.

Authors:  Jianguo Zhang; Junya Zhu; Lei Yang; Chengqi Guan; Runzhou Ni; Yuchan Wang; Lili Ji; Ye Tian
Journal:  Tumour Biol       Date:  2015-03-29

4.  Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).

Authors:  Sudha Korwar; Benjamin L Morris; Hardik I Parikh; Robert A Coover; Tyler W Doughty; Ian M Love; Brendan J Hilbert; William E Royer; Glen E Kellogg; Steven R Grossman; Keith C Ellis
Journal:  Bioorg Med Chem       Date:  2016-04-20       Impact factor: 3.641

5.  Compartmentation of metabolites in regulating epigenome of cancer.

Authors:  Zhiqiang Zhao; Li Wang; Lijun Di
Journal:  Mol Med       Date:  2016-04-18       Impact factor: 6.354

6.  Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Authors:  Konstantinos K Tsilidis; Ruth C Travis; Paul N Appleby; Naomi E Allen; Sara Lindstrom; Fredrick R Schumacher; David Cox; Ann W Hsing; Jing Ma; Gianluca Severi; Demetrius Albanes; Jarmo Virtamo; Heiner Boeing; H Bas Bueno-de-Mesquita; Mattias Johansson; J Ramón Quirós; Elio Riboli; Afshan Siddiq; Anne Tjønneland; Dimitrios Trichopoulos; Rosario Tumino; J Michael Gaziano; Edward Giovannucci; David J Hunter; Peter Kraft; Meir J Stampfer; Graham G Giles; Gerald L Andriole; Sonja I Berndt; Stephen J Chanock; Richard B Hayes; Timothy J Key
Journal:  Am J Epidemiol       Date:  2012-03-29       Impact factor: 4.897

7.  High expression and prognostic role of CAP1 and CtBP2 in breast carcinoma: associated with E-cadherin and cell proliferation.

Authors:  Xiancheng Liu; Ninghua Yao; Jing Qian; Huiwei Huang
Journal:  Med Oncol       Date:  2014-02-13       Impact factor: 3.064

8.  PTEN regulation by Akt-EGR1-ARF-PTEN axis.

Authors:  Jianxiu Yu; Sharon S Zhang; Kan Saito; Scott Williams; Yutaka Arimura; Yuliang Ma; Yuehai Ke; Veronique Baron; Dan Mercola; Gen-Sheng Feng; Eileen Adamson; Tomas Mustelin
Journal:  EMBO J       Date:  2008-12-04       Impact factor: 11.598

9.  The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling.

Authors:  Prashanth Kumar Bajpe; Guus J J E Heynen; Lorenza Mittempergher; Wipawadee Grernrum; Iris A de Rink; Wouter Nijkamp; Roderick L Beijersbergen; Rene Bernards; Sidong Huang
Journal:  Mol Cell Biol       Date:  2013-06-17       Impact factor: 4.272

10.  p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein.

Authors:  Ya-Wen Chen; Seema Paliwal; Kyle Draheim; Steven R Grossman; Brian C Lewis
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.